Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Quetiapine Fumarate

FDA-approved product (tablet, oral), marketed as Quetiapine Fumarate, Seroquel, Seroquel Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Quetiapine Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bipolar disorder
  • Bipolar I disorder
  • Bipolar II disorder
  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diazepines, oxazepines, thiazepines and oxepines
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Quetiapine Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Quetiapine Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)

    NCT05085808 · start 2028-03-01

    Registered record
    Registry ID
    NCT05085808
    Conditions
    Delirium; Morality; Quality of Life; Psych; Treatment Side Effects
    Interventions
    Trazodone; Quetiapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2028-03-01
    Completion
    2030-12-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Morality; Quality of Life; Psych +1 more
    InterventionTrazodone; Quetiapine; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Sequential Multiple Assignment Randomized Trial for Bipolar Depression

    NCT06433635 · start 2024-10-01

    Registered record
    Registry ID
    NCT06433635
    Conditions
    Bipolar I Disorder; Depression
    Interventions
    Cariprazine; Aripiprazole/Escitalopram combination; Quetiapine; Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-10-01
    Completion
    2030-02-28
    Enrolment
    2,726

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder; Depression
    InterventionCariprazine; Aripiprazole/Escitalopram combination; Quetiapine; Lurasidone
    PhasePhase 4
    Registry statusActive not recruiting

  • Comparing Antipsychotic Medications in LBD Over Time

    NCT05590637 · start 2022-04-22

    Registered record
    Registry ID
    NCT05590637
    Conditions
    Parkinson's Disease Psychosis; Dementia With Lewy Bodies
    Interventions
    Pimavanserin; Quetiapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-04-22
    Completion
    2027-02
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis; Dementia With Lewy Bodies
    InterventionPimavanserin; Quetiapine
    PhasePhase 4
    Registry statusRecruiting

  • Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    NCT04312503 · start 2020-07-13

    Registered record
    Registry ID
    NCT04312503
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-13
    Completion
    2022-10-31
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    PhaseNot recorded
    Registry statusCompleted

  • Quetiapine Treatment for Pediatric Delirium

    NCT03572257 · start 2019-04-15

    Registered record
    Registry ID
    NCT03572257
    Conditions
    Delirium
    Interventions
    Quetiapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2019-04-15
    Completion
    2020-03-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium
    InterventionQuetiapine; Placebo
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

    NCT03568500 · start 2018-05-21

    Registered record
    Registry ID
    NCT03568500
    Conditions
    Schizophrenia; Schizoaffective Disorder; First Episode Psychosis
    Interventions
    Digital Medicine System; Aripiprazole; Olanzapine; Quetiapine; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-21
    Completion
    2019-09-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; First Episode Psychosis
    InterventionDigital Medicine System; Aripiprazole; Olanzapine; Quetiapine +1 more
    PhasePhase 4
    Registry statusCompleted

  • Lithium Versus Quetiapine in Treatment Resistant Depression

    NCT03004521 · start 2016-11

    Registered record
    Registry ID
    NCT03004521
    Conditions
    Depressive Disorder, Treatment-Resistant
    Interventions
    Quetiapine; Lithium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-11
    Completion
    2021-08
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Treatment-Resistant
    InterventionQuetiapine; Lithium
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    NCT02307396 · start 2015-02-01

    Registered record
    Registry ID
    NCT02307396
    Conditions
    Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    Interventions
    Olanzapine; Amisulpride; Risperidone; Haloperidol; Quetiapine; Perphenazine; Sulpiride; bromperidol; Zuclopenthixol; Thioridazine; Paliperidone; Ziprasidone; Benperidol; Fluspirilene; Pimozide; Perazine; Fluphenazine; Flupentixole; Sertindole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    InterventionOlanzapine; Amisulpride; Risperidone; Haloperidol +15 more
    PhasePhase 4
    Registry statusCompleted

  • Neuroendocrine and Metabolite Substrates in Schizophrenia

    NCT02423096 · start 2013-12

    Registered record
    Registry ID
    NCT02423096
    Conditions
    Schizophrenia
    Interventions
    Risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2013-12
    Completion
    2016-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone
    PhaseNot recorded
    Registry statusUnknown

  • Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

    NCT01893229 · start 2013-09

    Registered record
    Registry ID
    NCT01893229
    Conditions
    Bipolar Disorder
    Interventions
    Lithium; Valproate; Oxcarbazepine; Quetiapine; Olanzapine; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-09
    Completion
    2015-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionLithium; Valproate; Oxcarbazepine; Quetiapine +2 more
    PhasePhase 4
    Registry statusUnknown

  • 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

    NCT01844700 · start 2013-07

    Registered record
    Registry ID
    NCT01844700
    Conditions
    High Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    Interventions
    Ziprasidone; aripiprazole, quetiapine, or risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2014-04
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    InterventionZiprasidone; aripiprazole, quetiapine, or risperidone
    PhasePhase 4
    Registry statusTerminated

  • The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope

    NCT01357967 · start 2011-05

    Registered record
    Registry ID
    NCT01357967
    Conditions
    Major Depressive Disorder
    Interventions
    SSRI monotherapy; Seroquel XR adjunctive
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2013-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionSSRI monotherapy; Seroquel XR adjunctive
    PhasePhase 4
    Registry statusUnknown

  • Post-Traumatic Stress Disorder (PTSD) and Seroquel

    NCT01066156 · start 2010-02

    Registered record
    Registry ID
    NCT01066156
    Conditions
    Post-Traumatic Stress Disorder
    Interventions
    Seroquel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-02
    Completion
    2015-03
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Stress Disorder
    InterventionSeroquel
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

    NCT00954122 · start 2009-09

    Registered record
    Registry ID
    NCT00954122
    Conditions
    Schizophrenia
    Interventions
    Quetiapine XR (Seroquel XR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-04
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionQuetiapine XR (Seroquel XR)
    PhasePhase 4
    Registry statusCompleted

  • A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium

    NCT00954603 · start 2009-06

    Registered record
    Registry ID
    NCT00954603
    Conditions
    Delirium
    Interventions
    quetiapine; haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2012-07
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium
    Interventionquetiapine; haloperidol
    PhasePhase 3
    Registry statusTerminated